Embedded Files
DelveInsight's comprehensive 2025 analysis of the Sarcopenia pipeline delivers extensive intelligence on over 18 companies and more than 20 investigational therapies currently advancing through development. This detailed examination encompasses drug candidate profiles across all developmental phases, from preclinical research through clinical trials. The assessment evaluates therapeutic candidates by product classification, developmental phase, administration method, and molecular structure, while also documenting discontinued programs in this therapeutic area.
Explore our latest breakthroughs in Sarcopenia Research. Learn more about our innovative pipeline today! @ Sarcopenia Pipeline Outlook
Key Highlights from the Pipeline Analysis
Key Highlights from the Pipeline Analysis
October 2025 marked a significant milestone when Daewoong Pet, a division of Daewoong Pharmaceutical, initiated groundbreaking work on the first sarcopenia treatment for companion animals. This collaborative venture with Rat Bio, the Korea Institute of Science and Technology (KIST), and Sungkyunkwan University represents a pioneering approach to addressing age-related muscle deterioration in pets, mirroring the condition observed in humans.
The current landscape shows a dynamic field with over 18 companies actively advancing more than 20 therapeutic candidates for sarcopenia management.
Key pharmaceutical developers include Biophytis, Epirium Bio, Turn Biotechnologies, Immunis, Oncocross, BPGbio, Inc., among others.
Notable investigational therapies comprise AMC6156 0.1mg, Bimagrumab, MK-0773, REGN1033 (SAR391786), LPCN 1148, BIO101, Olimel N12, Glucose IV, Testosterone Enanthate, Finasteride, and additional candidates.
Stay informed about the cutting-edge advancements in Sarcopenia treatments. Download for updates and be a part of the revolution in Musculoskeletal Care @ Sarcopenia Clinical Trials Assessment
Understanding Sarcopenia
Understanding Sarcopenia
Sarcopenia represents a progressive, age-associated disorder marked by declining skeletal muscle mass, diminished strength, and impaired physical function. This condition predominantly impacts elderly individuals and correlates with heightened fall risk, frailty development, decreased mobility, and deteriorating life quality. Although aging serves as the principal catalyst, additional contributing elements encompass chronic medical conditions, inflammatory processes, endocrine alterations, inadequate dietary intake, and sedentary lifestyle. The World Health Organization (WHO) has formally classified sarcopenia as a distinct medical condition, and it continues gaining prominence in clinical investigations given its substantial implications for aging demographics.
Featured Investigational Therapies
Featured Investigational Therapies
BIO101: Biophytis Sarconeos (BIO101) represents an orally administered small molecule that functions as a proto-oncogene protein c-mas-1 agonist. Evidence from laboratory and preclinical investigations suggests that Sarconeos (BIO101) enhances biological resilience by activating the MAS receptor, potentially improving muscular performance while maintaining strength, mobility, and breathing capacity across various age-related and muscle-wasting disorders. During Phase II clinical evaluation, the compound demonstrated excellent tolerability at dosages of 175 mg twice daily and 350 mg twice daily, with no product-related Serious Adverse Events (SAEs). This therapeutic candidate is presently undergoing Phase II clinical assessment for sarcopenia treatment.
MF-300: Epirium Bio MF-300 is an orally available small molecule that creates a reversible bond with the Prostaglandin E2 (PGE2)-binding domain of 15-hydroxyprostaglandin dehydrogenase (15-PGDH), an enzyme responsible for converting PGE2 into an inactive form. Through target engagement, MF-300 suppresses 15-PGDH activity, thereby stabilizing and elevating PGE2 concentrations in laboratory assays and skeletal muscle tissue in animal models. Research shows that 15-PGDH gene expression increases in muscle tissue concurrent with age-related muscle weakness onset in both humans and rodents. PGE2, a lipid signaling compound with numerous positive effects on the motor unit—including enhanced muscle quality and optimized neuromuscular junction performance—becomes depleted in aged mouse skeletal muscle due to heightened 15-PGDH activity. Blocking 15-PGDH in aging muscle may offer a therapeutic approach to restore physiological PGE2 levels, thereby improving muscle quality and performance. This compound is currently advancing through Phase I development for sarcopenia treatment.
TRN005: Turn Biotechnologies TRN-005 is a specialized formulation designed to rebuild muscle mass and strength while reversing age-related conditions that limit individuals' capacity to maintain active lifestyles. Preclinical data revealed improvements in stem cell proliferation and differentiation, accelerated muscle repair, enhanced fiber thickness, and increased force generation. This candidate is currently in preclinical development stages for sarcopenia treatment.
Learn more about Sarcopenia Drugs opportunities in our ground breaking Sarcopenia research and development projects @ Sarcopenia Unmet Needs
Report Coverage and Analysis
Report Coverage and Analysis
This comprehensive pipeline report delivers intelligence on:
Detailed profiles of pharmaceutical companies developing sarcopenia therapeutics, including aggregate therapy portfolios from each organization.
Assessment of therapeutic candidates classified by early-stage, mid-stage, and late-stage development phases.
Active and inactive (dormant or discontinued) pipeline programs across participating companies.
Categorization of investigational drugs by developmental stage, delivery route, target receptor, treatment approach (monotherapy or combination), mechanism of action, and molecular classification.
In-depth examination of partnerships (industry collaborations and academic alliances), licensing arrangements, and funding details relevant to future market advancement.
Featured Companies
Featured Companies
Biophytis, Epirium Bio, Turn Biotechnologies, Immunis, Oncocross, BPGbio, Inc. and others.
Route of Administration Categories
Route of Administration Categories
Pipeline products are organized by delivery method:
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Molecular Type Classifications
Molecular Type Classifications
Investigational products are categorized by molecular structure:
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Discover the latest advancements in Sarcopenia treatment by visiting our website. Stay informed about how we're transforming the future of Musculoskeletal @ Sarcopenia Market Drivers and Barriers, and Future Perspectives
Report Scope
Report Scope
Geographic Coverage: Global
Featured Companies: Biophytis, Epirium Bio, Turn Biotechnologies, Immunis, Oncocross, BPGbio, Inc., and others
Pipeline Therapies: AMC6156 0.1mg, Bimagrumab, MK-0773, REGN1033 (SAR391786), LPCN 1148, BIO101, Olimel N12, Glucose IV, Testosterone Enanthate, Finasteride, and others
Product Type Assessment: Monotherapy, Combination therapy, Mono/Combination approaches
Clinical Stage Assessment: Discovery, Preclinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Sarcopenia Pipeline on our website @ Sarcopenia Emerging Drugs and Companies
Report Structure
Report Structure
Introduction
Executive Summary
Sarcopenia Overview
Pipeline Therapeutics for Sarcopenia
Therapeutic Assessment
Analytical Perspective
Mid-Stage Products (Phase II)
BIO101: Biophytis
Early-Stage Products (Phase I)
MF-300: Epirium Bio
Preclinical Stage Products
TRN005: Turn Biotechnologies
Discontinued Products
Company Profiles
Key Product Highlights
Unmet Medical Needs
Market Drivers and Obstacles
Future Perspectives and Conclusions
Analyst Perspectives
Appendix
About DelveInsight
About DelveInsight
DelveInsight operates as a premier healthcare-focused market research and consulting organization, delivering high-caliber market intelligence and analytical insights that empower informed business decision-making. Supported by seasoned industry specialists and comprehensive expertise in life sciences and healthcare domains, the firm provides tailored research solutions and strategic insights to a global client base. Engage with our team to access premium-quality, precise, and current intelligence that positions you ahead of market developments.
Contact Us:
Kanishk
Page updated
Google Sites
Report abuse